Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... the specific mutations that confer clinical resistance to marketed CML therapies imatinib (Gleevec®), dasatinib (Sprycel®), and nilotinib (Tasigna®). ...
2009 NOV 23 ... treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted ...
2009 NOV 16 ... "KIT alterations have been identified in melanoma and treatment with imatinib has met with some success. However, the relationship between KIT and melanoma histology ...
2009 NOV 23 ... "We aimed to compare the cytogenetic and molecular analyses in the assessment of imatinib mesylate response in patients suffering the chronic phase of chronic myelocytic leukemia ...
2009 NOV 16 ... "First-line-treatment for chronic myelogenous leukemia (CML) is imatinib, but some patients do not respond or develop resistance to the drug, leading to ...
2009 NOV 16 ... to recent research from the United States, "The introduction of the BCR-ABL inhibitor imatinib revolutionized the treatment of patients with chronic myeloid leukemia (CMIL). However, ...
2009 NOV 23 ... carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC," scientists in the United States report. "with ...
2009 NOV 23 ... t(9;22), which leads to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec), treatment was limited and provided only limited survival benefit," ...
2009 NOV 16 ... According to a study from Athens, Greece, "Phase I-II studies indicate that imatinib is active in glioblastoma multiforme. To better understand the molecular and clinical ...
2009 NOV 16 ... could be completely blocked by adding a c-kit/tyrosine kinase inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, http://www.novartis.com), to the ...
2009 NOV 24 ... implants. Furthermore, two small molecule inhibitors of the PDGFR tyrosine kinase (i.e., imatinib and dasatinib) exerted negative effects on fSMC and mSMC growth in ex vivo cultures, ...
2009 NOV 16 ... This relocalization was clearly correlated to the inhibition of TK activity because imatinib, a specific inhibitor of the V560G mutant, inactive on the catalytic D816V mutant, ...
2009 NOV 16 ... MC mediator-related symptoms." "We examined the effects of three KIT TKI, imatinib, nilotinib, and midostaurin, on IgE-dependent mediator release in normal human blood ...
2009 NOV 9 ... AML but are expected to have minimal impact on patient outcomes. Gleevec (imatinib; Novartis) is the only molecular targeted therapy used extensively in the treatment of ...
2009 NOV 23 ... TAp63 accumulation and eventually cell death. Treatment with the c-Abl kinase inhibitor imatinib counteracts these cisplatin-induced effects. Taken together, these data support a model ...
2009 NOV 16 ... to recent research published in the journal Molecular Cancer, "The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABLI, has had a major impact in ...
2009 NOV 9 ... "Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic ...
2009 NOV 23 ... study (www.hovon.nl) and received two cycles of cytarabine 200 mg/m(2) for 7 days and imatinib 800 mg, q.d., continuously. Swiftly, he attained a complete and durable cytogenetic ...
2009 NOV 9 ... "Early detection of resistance development is crucial for imatinib-based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish ...
